Case Study

Metabolon Elucidates a Link Between Short Chain Fatty Acids and Colorectal Cancer in Cystic Fibrosis Patients

Metabolon’s Short Chain Fatty Acids Targeted Panel was used to identify a link between short chain fatty acids (SCFAs) and colorectal cancer (CRC) in cystic fibrosis (CF) patients.

This study shows that the microbiome composition and SCFAs levels in the gut of patients with CF may contribute to the increased risk of CRC in this population. Metabolomics is a powerful tool for studying the role of SCFAs in disease and has the potential to provide new insights and therapeutic targets for a range of conditions.

Talk With An Expert About Your Project

Microbiome, Short Chain Fatty Acids, and Colon Cancer

The Challenge: Understanding Cystic Fibrosis and the Increased Risk of Colorectal Cancer

Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CFTR codes for a protein that regulates salt and water transport in and out of cells. In the past, CF was often fatal in childhood, with many children dying before reaching adolescence. However, with advances in medical care, the outlook for people with CF has improved significantly over the past few decades. Today, many individuals with CF can live into adulthood and lead relatively normal lives. Yet, as more individuals with CF are now reaching adulthood, adults with CF seem to have an increased and early risk of malignancy, including a higher incidence of colorectal cancer (CRC). Compared to the general population, CF patients are 5 to 10 times more likely to develop CRC.¹ Unfortunately, the molecular mechanisms underlying the increased risk of CRC in patients with CF are poorly understood.

Metabolon Insight: Metabolomics Analysis of Short Chain Fatty Acids in Adults With and Without Cystic Fibrosis

This study utilized Metabolon’s Short Chain Fatty Acids Targeted Panel to profile colonic aspirates from adults with (n = 21) and without (n = 21) CF undergoing CRC screening.² Metabolon offered this group the most comprehensive solution to characterize and compare gut SCFA composition of adult patients with and without CF and to determine whether SCFAs are associated with colonic adenomas.

The Solution: Associations Between the Microbiome, Short Chain Fatty Acids, and Colon Cancer in CF Patients

Colonic aspirates were first characterized via 16S rRNA sequencing. In line with prior reports, patients with CF had profound alterations in their gut microbiota, including reduced microbial diversity and reductions in several SCFA-producing taxa. CF patients with adenomas had an increased relative abundance of B. fragilis, a pathogen strongly linked to the development of CRC. This alteration was not observed in non-CF patients with adenomas.

Metabolon’s Short Chain Fatty Acids Targeted Panel was also used to characterize colonic aspirates. CF patients had significantly reduced levels of valeric acid (valerate) and caproic acid (hexanoate) compared to non-CF patients. The research group also assessed for associations between gut microbiome composition, metabolite levels, and adenomas in CF patients. CF microbiome composition was found to be significantly associated with isovaleric acid (isovalerate) concentration and the presence of adenomas.

The Outcome: Metabolomics and the Role of Short Chain Fatty Acids in Colorectal Cancer Risk

These findings suggest that the microbiome composition and SCFAs levels in the gut of patients with CF may contribute to the increased risk of CRC in this population. Metabolomics is a powerful tool for studying the role of SCFAs in disease and has the potential to provide new insights and therapeutic targets for a range of conditions. Further studies are needed to elucidate the interplay between SCFAs and microbiota composition and the biological effects of SCFAs in both CF and non-CF populations.

References

1. About colorectal cancer. Cystic Fibrosis Foundation. https://www.cff.org/managing-cf/about-colorectal-cancer. Accessed March 30, 2023.

2. Baldwin-Hunter BL, Rozenberg FD, Annavajhala MK, et al. The gut microbiome, short chain fatty acids, and related metabolites in cystic fibrosis patients with and without colonic adenomas. J Cyst Fibros. Jan 28 2023;doi:10.1016/j.jcf.2023.01.013

Related Case Studies

See All Case Studies

Metabolomics finds PanK4 to be an Important Regulator of Glucose Uptake and Lipid Metabolism

Find out more $

Metabolomics provides insight into the pathology of sudden infant death syndrome and identifies biomarker candidates

Find out more $

Metabolomics Reveals Beneficial Changes to Metabolite Profiles During Diabetes Remission

Find out more $

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.